HUMANIZED MULTIVALENT PROTEIN CONJUGATES
The present invention relates to peptide sequences having a high degree of humanness and/or the ability to be expressed in appreciable levels in culture media, such as in E. coli. The peptides can be covalently attached via an alpha-helical peptide linker to a polymer backbone. The invention further relates to methods of preparing the peptides, polymer conjugates comprising the peptides, and pharmaceutical compostions thereof..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 21. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
JACKSON WESLEY M [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-21, Last update posted on www.tib.eu: 2024-01-30, Last updated: 2024-02-02 |
|---|
| Patentnummer: |
US2023406916 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018884687 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018884687 | ||
| 003 | DE-627 | ||
| 005 | 20240202085744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240105s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018884687 | ||
| 035 | |a (EPA)US2023406916 | ||
| 035 | |a (EPA)88330387 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a JACKSON WESLEY M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HUMANIZED MULTIVALENT PROTEIN CONJUGATES |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-21, Last update posted on www.tib.eu: 2024-01-30, Last updated: 2024-02-02 | ||
| 520 | |a The present invention relates to peptide sequences having a high degree of humanness and/or the ability to be expressed in appreciable levels in culture media, such as in E. coli. The peptides can be covalently attached via an alpha-helical peptide linker to a polymer backbone. The invention further relates to methods of preparing the peptides, polymer conjugates comprising the peptides, and pharmaceutical compostions thereof. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a TWITE AMY A |4 aut | |
| 700 | 0 | |a BARNEBEY ADAM |4 aut | |
| 700 | 0 | |a BRIER LIVIA WILZ |4 aut | |
| 700 | 0 | |a MCFARLAND JESSE M |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 21. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88330387/publication/US2023406916A1?q=US2023406916 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 21 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 12 | ||